Literature DB >> 19509101

Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome.

María-José Barahona1, Nuria Sucunza, Eugenia Resmini, José-Manuel Fernández-Real, Wifredo Ricart, José-María Moreno-Navarrete, Teresa Puig, Jordi Farrerons, Susan M Webb.   

Abstract

OBJECTIVE: Although increased central fat mass is characteristic of active Cushing's syndrome (CS), little is known about body composition and secretion of adipokines after long-term recovery of CS. The aim of this study was to evaluate central fat mass and its correlation with adipokines and cardiovascular risk factors in patients after long-term remission of CS.
METHODS: Thirty-seven women with CS in remission (27 of pituitary and 10 of adrenal origin; mean age, 50 +/- 14 yr; mean time of hormonal cure, 11 +/- 6 yr) were enrolled and compared to 14 women with active CS and 85 gender-, age-, and body mass index-matched healthy controls. Total and trunk fat mass were measured by dual-energy x-ray absorptiometry scanning. Laboratory parameters and adipokine levels [including adiponectin, visfatin, soluble TNFalpha-receptor 1 (sTNF-R1), sTNF-R2, and IL-6] were measured.
RESULTS: Cured CS patients had more total and trunk fat mass than controls. Cured and active CS had higher levels of sTNF-R1 and IL-6 and lower adiponectin levels than controls. Higher insulin levels and blood pressure in both groups of CS patients and higher apolipoprotein B in cured CS were observed compared to controls. sTNF-R1 correlated positively with percentage of trunk fat mass and remained significant after adjusting for anthropometric parameters.
CONCLUSION: Despite long-term cure, patients who have suffered CS exhibit persistent accumulation of central fat, as in active hypercortisolemia, with the consequent unfavorable adipokine profile, leading to a state of low-grade inflammation. This situation determines a persistent and increased cardiovascular risk in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509101     DOI: 10.1210/jc.2009-0766

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  46 in total

Review 1.  Characterization of persistent and recurrent Cushing's disease.

Authors:  Nina K Sundaram; Alessia Carluccio; Eliza B Geer
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

2.  White matter alterations in the brains of patients with active, remitted, and cured cushing syndrome: a DTI study.

Authors:  P Pires; A Santos; Y Vives-Gilabert; S M Webb; A Sainz-Ruiz; E Resmini; I Crespo; M de Juan-Delago; B Gómez-Anson
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-30       Impact factor: 3.825

3.  Pituitary tumors: coping with ‘cured’ pituitary tumors.

Authors:  Susan M Webb
Journal:  Nat Rev Endocrinol       Date:  2011-05       Impact factor: 43.330

4.  Cortisol level after dexamethasone suppression test in patients with non-functioning adrenal incidentaloma is positively associated with the duration of reactive hyperemia response on microvascular bed.

Authors:  M P de Paula; A B Moraes; M das Graças Coelho de Souza; E M R Cavalari; R C Campbell; G da Silva Fernandes; M L F Farias; L M C Mendonça; M Madeira; E Bouskela; L G Kraemer-Aguiar; L Vieira Neto
Journal:  J Endocrinol Invest       Date:  2020-07-19       Impact factor: 4.256

5.  Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI.

Authors:  Eliza B Geer; Wei Shen; Erika Strohmayer; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2012-03-14       Impact factor: 5.958

6.  Chronic Corticosterone Treatment During Adolescence Has Significant Effects on Metabolism and Skeletal Development in Male C57BL6/N Mice.

Authors:  Scott A Kinlein; Ziasmin Shahanoor; Russell D Romeo; Ilia N Karatsoreos
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

Review 7.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

8.  Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.

Authors:  V Guarnotta; G Pizzolanti; A Ciresi; C Giordano
Journal:  J Endocrinol Invest       Date:  2018-02-02       Impact factor: 4.256

9.  Soluble TNFα-receptor 1 as a predictor of coronary calcifications in patients after long-term cure of Cushing's syndrome.

Authors:  María-José Barahona; Eugenia Resmini; David Viladés; José-Manuel Fernández-Real; Wifredo Ricart; José-María Moreno-Navarrete; Guillem Pons-Lladó; Rubén Leta; Susan M Webb
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

10.  Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients.

Authors:  Jessica K Lambert; Levana Goldberg; Sofia Fayngold; Jane Kostadinov; Kalmon D Post; Eliza B Geer
Journal:  J Clin Endocrinol Metab       Date:  2013-02-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.